DOWNSTREAM PROCESSING FEATURED ARTICLES
Theratechnologies Inc. (TSX:TH)(NASDAQ:THER) today reported that the US Patent and Trademark Office (USPTO) has granted a patent (US Patent No. 8,361,964) for its second generation growth-hormone releasing factor (GRF) peptide, TH1173, providing for patent protection beyond 2030.
-
Galapagos Announces GSK2586184 JAK1 Molecule Progresses To Phase 2 Studies
Galapagos NV (Euronext: GLPG) announced today that GlaxoSmithKline plan to initiate Phase 2 studies with GSK2586184 (formerly GLPG0778) in systemic lupus erythematosus (SLE) and chronic plaque psoriasis.
-
Kimberly-Clark Professional Launches Innovative RightCycle Program To Recycle Single-Use Cleanroom And Laboratory Gloves And Garments
To provide cleanrooms and laboratories with effective solutions to mitigate waste and enhance Corporate Social Responsibility (CSR) and sustainability efforts, Kimberly-Clark Professional has introduced RightCycle – the first large-scale recycling effort for nontraditional cleanroom waste.
-
Pfenex Awarded Contract By The NIAID To Develop An Alternative Delivery Method For rPA-based Anthrax Vaccine
Pfenex Inc. Awarded Contract by the National Institute of Allergy and Infectious Diseases (NIAID) to Develop an Alternative Delivery Method for its Recombinant Protective Antigen (rPA)-based Anthrax Vaccine
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
Important Considerations For Implementing A Single-Use Biomanufacturing Strategy
Recent trends in biomanufacturing technology and the biopharmaceutical market are supporting the increased adoption of single-use (SU) manufacturing systems. On the demand-side, the biopharma industry is focusing on niche and rare diseases with smaller patient populations, resulting in the need for smaller, more agile biomanufacturing capacity. By Jodi M. Zobrist and Nicole W. O'Brien, Ph. D., Gallus Biopharmaceuticals, LLC
-
Biomanufacturing Flexibility
This white paper from BIO-G looks at how to create flexible, agile manufacturing facilities to respond to the current glut of biomanufacturing capacity and industry consolidation. Future proofing these facilities for higher titers and multiple product lines is also explored.
-
Monoclonal Antibody Purification Platform Using High-Capacity Protein A And Mixed-Mode Chromatography
The first step in purification of an important class of therapeutic proteins, the polyclonal or monoclonal antibodies (mAbs), is their capture from plasma or tissue culture supernatants. Protein A–based media are by far the most common class of affinity products used for this purpose.
-
Connection Technology Advances Closed System Processing
The global demand for new biologics and vaccines, combined with the growing emergence of biosimiliars, is challenging drugmakers to re-evaluate their processes and seek ways to make them more flexible, reliable, and cost-effective. By John Boehm, Colder Products Company
-
Improving Aggregate Removal From mAb Feed Using Cation Exchange Chromatography
Researchers in the field of chromatography have required ever more sophisticated and selective methods for removing aggregates from the monomer.
-
Protein A Alternatives: Mixed Mode Resins For High Throughput mAb Feedstocks
Mixed mode resins can serve as an alternative to protein A in intermediate processing. Implementation of mixed mode resins can reduce water required for filtration and time for column loading.